Enliven Therapeutics, Inc.

By person

33 insiders · 403 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

ORBIMED ADVISORS LLC entity

10% owner

$25.00M (2)

$74.56M (8)

−$49.56M

6,555,102

8.95%

$389.02M

—

5AM Partners VI, LLC entity

10% owner

—

$29.80M (8)

−$29.80M

635,341

0.8671%

$37.71M

−75.5%

Bonita David P

Director

$25.00M (2)

—

+$25.00M

1,666,666

2.27%

$98.91M

—

Gupta Rishi

Director

—

$22.88M (2)

−$22.88M

7,663,349

10.46%

$454.79M

+864.0%

RA CAPITAL MANAGEMENT, L.P. entity

Former 10% owner

$14.83M (10)

—

+$14.83M

2,122,465

2.90%

$125.96M

—

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER

—

$11.75M (60) scheduled

−$11.75M

758,938

1.04%

$45.04M

—

Chin Mark

Director

$11.00M (2)

—

+$11.00M

2,344,072

3.20%

$139.11M

—

Derynck Mika K

Director

—

$9.56M (1) scheduled

−$9.56M

0.0000%

$0.00

—

Kintz Samuel

PRESIDENT AND CEO

—

$7.41M (51) scheduled

−$7.41M

890,392

1.22%

$52.84M

—

Patel Anish

CHIEF OPERATING OFFICER

—

$5.90M (45) scheduled

−$5.90M

235,011

0.3207%

$13.95M

—

Collins Helen Louise

CHIEF MEDICAL OFFICER

—

$5.66M (23) scheduled

−$5.66M

25,000

0.0341%

$1.48M

—

New Enterprise Associates 14, L.P. entity

10% owner

$7.60M (1)

$2.27M (34)

+$5.33M

2,611,050

3.56%

$154.96M

—

Dalton Barbara

Director

$5.00M (1)

—

+$5.00M

1,557,722

2.13%

$92.45M

—

PFIZER INC entity

10% owner

$5.00M (1)

—

+$5.00M

1,557,722

2.13%

$92.45M

—

Leonard Braden Michael

10% owner

$964.52K (7)

$5.36M (6)

−$4.40M

1,997,774

2.73%

$118.56M

−23.7%

Hohl Benjamin

CHIEF FINANCIAL OFFICER

—

$4.21M (64) scheduled

−$4.21M

40,036

0.0546%

$2.38M

—

Rock Springs Capital Management LP entity

10% owner

$4.00M (1)

—

+$4.00M

523,411

0.7144%

$31.06M

—

Agger Mette Kirstine

Director

$3.00M (1)

—

+$3.00M

1,432,722

1.96%

$85.03M

—

Arix Bioscience plc entity

10% owner

$3.00M (1)

—

+$3.00M

1,554,558

2.12%

$92.26M

—

Lundbeckfond Invest A/S

10% owner

$3.00M (1)

—

+$3.00M

1,432,722

1.96%

$85.03M

—

Ballal Rahul D.

Director

—

$2.56M (12) scheduled

−$2.56M

22,341

0.0305%

$1.33M

—

Heyman Richard A.

Director

—

$1.09M (33) scheduled

−$1.09M

146,320

0.1997%

$8.68M

—

Kunkel Lori Anne

Director

—

$850.25K (5) scheduled

−$850.25K

41,884

0.0572%

$2.49M

−8.8%

MOTT DAVID M

Director

$313.59K (9)

—

+$313.59K

229,224

0.3128%

$13.60M

—

COMMODORE CAPITAL LP entity

10% owner

$177.22K (3)

—

+$177.22K

1,448,640

1.98%

$85.97M

+111.1%

GRAY MICHAEL

CFO & COO

—

$91.37K (3)

−$91.37K

27,610

0.0377%

$1.64M

+1,513%

Schwab Andrew J.

Director

—

960,383

1.31%

$57.00M

—

GOLDFISCHER CARL

Director

—

703,380

0.9600%

$41.74M

—

BAY CITY CAPITAL LLC entity

10% owner

—

703,380

0.9600%

$41.74M

—

H LUNDBECK A S

10% owner

—

522,499

0.7131%

$31.01M

+17.9%

Alexandria Venture Investments, LLC entity

10% owner

—

293,013

0.3999%

$17.39M

—

Bauer Jake

Director

—

87,372

0.1192%

$5.19M

—

Attie Kenneth

SVP, CMO

—

34,100

0.0465%

$2.02M

—

Enliven Therapeutics, Inc.

By person

Individual transactions

What was left out